

Performance

Learn more about our performance on our [Investor site](#).

Financial Performance

Three-year summary for the years ended December 31

(Millions, Except Per Share Data)				% Change	
	2025	2024	2023	25/24	24/23
Revenues	\$62,579	\$63,627	\$59,553	(2)	7
Reported net income ^(a)	\$7,771	\$8,031	\$2,119	(3)	*
Reported diluted EPS ^(a)	\$1.36	\$1.41	\$0.37	(3)	*
Adjusted income ^(b)	\$18,406	\$17,716	\$10,501	4	69
Adjusted diluted EPS ^(b)	\$3.22	\$3.11	\$1.84	4	69
Net cash provided by operating activities	\$11,704	\$12,744	\$8,700	(8)	46
Cash dividends paid	\$9,771	\$9,512	\$9,247	3	3

(a) Reported net income is defined as *Net income attributable to Pfizer Inc. common shareholders* in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Reported diluted earnings per share (EPS) is defined as diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP.

(b) Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP *Net income attributable to Pfizer Inc. common shareholders* and *EPS attributable to Pfizer Inc. common shareholders—diluted* before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. The Adjusted income and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and diluted EPS, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies. See the *Non-GAAP Financial Measure: Adjusted Income* section of *Management's Discussion and Analysis of Financial Condition and Results of Operations* in Pfizer's 2025 Annual Report on Form 10-K for an explanation of how management uses these non-GAAP measures, reconciliations to the most directly comparable U.S. GAAP measures and additional information.

* Indicates calculation not meaningful or results are greater than 100%.

Detailed information on our financial and operational performance can be found in our 2025 Annual Report on Form 10-K.

Top 10 Medicines and Vaccines

Take a look at our breakdown of the top medicines and vaccines by revenue from 2025.

● **\$7,961 million**
ELIQUIS® (apixaban)¹

● **\$6,494 million**
PREVNAR® Family²

● **\$6,380 million**
VYNDAQEL® Family³

● **\$4,367 million**
COMIRNATY®⁴

● **\$4,122 million**
IBRANCE®

● **\$2,362 million**
PAXLOVID® (nirmatrelvir tablets and ritonavir tablets)

● **\$2,194 million**
XTANDI® (enzalutamide)⁵

● **\$1,940 million**
PADCEV® (enfortumab vedotin-ejfv)

● **\$1,424 million**
NURTEC ODT®/VYDURA® (rimegepant)

● **\$1,087 million**
XELJANZ® (tofacitinib)


¹ ELIQUIS reflects alliance revenues and product revenues.

² PREVNAR Family includes Prevnar 20/Prevenar 20 (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult).

³ VYNDAQEL Family includes global revenues from VYNDAQEL, as well as revenues for VYNDAMAX in the U.S. and VYNMAC in Japan.

⁴ COMIRNATY refers to, as applicable, the current formulation of COMIRNATY (COVID-19 Vaccine, mRNA) 2025-2026 Formula as well as all prior authorized or approved formulations of the vaccine, which was first authorized in the U.S. during December 2020 pursuant to an Emergency Use Authorization (EUA).

⁵ XTANDI primarily reflects alliance revenues and royalty revenues.



View the interactive graph on the [Annual Review site](#).